Giovanna Attolini

Dr. Giovanna Attolini


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VFViscardo Paolo Fabbri
Viscardo Paolo Fabbri
Giuseppe BroggiGiuseppe Broggi
Giuseppe Broggi
GAGiovanna Attolini
Giovanna Attolini
Vincenzo L'ImperioVincenzo L'Imperio
Vincenzo L'Imperio
FPFabio Pagni
Fabio Pagni
Rosario CaltabianoRosario Caltabiano
Rosario Caltabiano
Background: Although Ki-67 is not included among the grading criteria in the current WHO Classification of Tumours of the Central Nervous System (CNS), it provides valuable, albeit limited, prognostic information. Immunohistochemistry for Ki-67 can reveal uneven proliferation patterns and assist in the assessment of mitotic counts. Several studies indicate that meningiomas with a proliferation index > 4% show recurrence rates comparable to CNS WHO grade 2 (atypical) tumors, while tumors with an index > 20% are associated with mortality rates similar to CNS WHO grade 3 (anaplastic) meningiomas. Issues related to Ki-67 assessment include interobserver variability, the use of different cut-off values among pathologists, and the presence of a complex inflammatory tumour microenvironment, which may lead to an overestimation of the proliferative index (PI). Methods: In this study, we describe how Double Staining Immunohistochemistry (dIHC) with EMA/Ki-67 better highlights neoplastic meningothelial cells compared with single-stain evaluation. Furthermore, the application of Digital Pathology provides quantitative digital data that allow a more accurate assessment of proliferation. Results: Ki-67 expression varied by grade, with digital image analysis (dIHC) showing high agreement with manual assessments. dIHC improved accuracy in evaluating diagnostic and proliferative markers within tumor samples. Conclusions: dIHC combined with DP can support and standardize the evaluation of the proliferative index in meningiomas in routine diagnostic practice.

14 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
VFViscardo Paolo Fabbri
Viscardo Paolo Fabbri
Giuseppe BroggiGiuseppe Broggi
Giuseppe Broggi
GAGiovanna Attolini
Giovanna Attolini
Vincenzo L'ImperioVincenzo L'Imperio
Vincenzo L'Imperio
FPFabio Pagni
Fabio Pagni
Rosario CaltabianoRosario Caltabiano
Rosario Caltabiano
Background Although several studies showed that high immunohistochemical Ki-67 index negatively influences the clinical course of meningiomas, especially in grade 1 and 2 neoplasm, the 5th edition of the World Health Organi-zation (WHO) Classification of Tumours of the Central Nervous System does not recognize it as a prognostic crite-rion. Issues related to Ki-67 assessment include interobserver variability, different cut-off values used by pathologists and the presence of a complex inflammatory tumour microenvironment, that may overestimate the proliferative index (PI). Methods In this paper, we described as Double Staining Immunohistochemistry (dIHC) EMA/Ki-67 highlights only neoplastic meningocytes better tha single slices evcaluation; then the application of Dig-ital Pathology (DP) can provide digital information for a more accurate count. Results and Future prospective dIHC and DP can support and standardize the evaluation of PI in meningiomas in daily routine.